A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis

Jane R Schwebke,Belvia A Carter,Arthur S Waldbaum,Kathy J Agnew,Jeremy R A Paull,Clare F Price,Alex Castellarnau,Philip McCloud,George R Kinghorn

European Journal of Obstetrics & Gynecology and Reproductive Biology: X（2021）

引用 12|浏览10

暂无评分

摘要

•Recurrent bacterial vaginosis impacts on women and carries a high financial burden.•Astodrimer 1% Gel was superior to placebo for prevention of recurrent BV.•Astodrimer 1% Gel was well tolerated when used every second day for 16 weeks.•Results support the use of Astodrimer 1% Gel for prevention of recurrent BV.

查看译文

关键词

Astodrimer Gel,Bacterial vaginosis,Biofilm,Prevention,Recurrent bacterial vaginosis,SPL7013,VivaGel

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要